Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Renal Cell 32Sarcoma 29Neoplasm Metastasis 17Ovarian Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Kidney Neoplasms 6Recurrence 5Lung Neoplasms 5Liposarcoma 5Thyroid Neoplasms 4Melanoma 4Leiomyosarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Pancreatic Neoplasms 3Neurofibrosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Chondrosarcoma, Extraskeletal Myxoid 3Advanced Cancers 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2

Interventions

Sorafenib 3pazopanib 2Sunitinib 2eribulin 1Temozolomide 1Sirolimus 1Irinotecan 1Erlotinib Hydrochloride 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Refractory Solid Tumors × pazopanib × Clear all
NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡